Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials

Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems...

Descripción completa

Detalles Bibliográficos
Autores principales: Nada, Khaled M., Nishi, Shawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930786/
https://www.ncbi.nlm.nih.gov/pubmed/33718791
http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.009
_version_ 1783660156460990464
author Nada, Khaled M.
Nishi, Shawn
author_facet Nada, Khaled M.
Nishi, Shawn
author_sort Nada, Khaled M.
collection PubMed
description Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems.
format Online
Article
Text
id pubmed-7930786
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-79307862021-03-12 Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials Nada, Khaled M. Nishi, Shawn Mayo Clin Proc Innov Qual Outcomes Review Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems and no clear benefit of one over the other. This article provides an overview of the two largest prospective trials performed with the FDA-approved valve systems. Elsevier 2020-12-11 /pmc/articles/PMC7930786/ /pubmed/33718791 http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.009 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Nada, Khaled M.
Nishi, Shawn
Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
title Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
title_full Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
title_fullStr Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
title_full_unstemmed Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
title_short Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
title_sort endoscopic lung volume reduction: review of the emprove and liberate trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930786/
https://www.ncbi.nlm.nih.gov/pubmed/33718791
http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.009
work_keys_str_mv AT nadakhaledm endoscopiclungvolumereductionreviewoftheemproveandliberatetrials
AT nishishawn endoscopiclungvolumereductionreviewoftheemproveandliberatetrials

Ejemplares similares